文献速递艾滋病与性传播感染

CD4+细胞计数>200个/毫升且抗逆转录病毒治疗病毒学抑制的HIV感染成人中带状疱疹活疫苗的安全性与免疫原性

Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
PubMed 文献 · Clin Infect Dis · 2018-01-01

在CD4+计数分层(200-349或≥350个/µL)且ART病毒学抑制的HIV感染成人中开展随机双盲安慰剂对照试验,395人按3:1在第0天和第6周接种带状疱疹活疫苗或安慰剂。两剂疫苗安全性终点与安慰剂无显著差异,第12周VZV抗体滴度疫苗组高于安慰剂组,结论为两剂疫苗安全且有免疫原性。

要点

  • 395名CD4+≥200个/µL且病毒学抑制的HIV感染者随机接种两剂带状疱疹活疫苗或安慰剂。
  • 安全性终点疫苗组5.1% vs 安慰剂组2.1%,差异无统计学显著(P=0.26)。
  • 第12周VZV抗体滴度疫苗组高于安慰剂组,1剂与2剂后抗体滴度相似。

核心结论

  • 在CD4+计数≥200个/µL且ART病毒学抑制的HIV感染成人中,两剂带状疱疹活疫苗安全且有免疫原性。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,HIV感染且ART病毒学抑制的成人按CD4+计数(200-349或≥350个/µL)分层,按3:1随机在第0天和第6周接种带状疱疹活疫苗或安慰剂。
  • 共395名参与者(带状疱疹活疫苗296例 vs 安慰剂99例),84%为男性,47%白人,29%黑人,22%西班牙裔,中位年龄49岁。

主要发现

  • 安全性终点发生在带状疱疹活疫苗组15例 vs 安慰剂组2例(5.1% [95%CI 2.9%-8.2%] vs 2.1% [95%CI 0.3%-7.3%];P=0.26)。
  • 注射部位反应发生在带状疱疹活疫苗组42%(95%CI 36.3%-47.9%) vs 安慰剂组12.4%(95%CI 6.6%-20.6%)(P<0.001)。
  • 第12周中位自然对数VZV抗体滴度带状疱疹活疫苗组为6.30(Q1,Q3,5.64,6.96) vs 安慰剂组5.48(Q1,Q3,4.63,6.44),总体P<0.001,高CD4+分层P=0.003。
  • 接种1剂或2剂带状疱疹活疫苗后VZV抗体滴度相似。
  • 聚合酶链反应确诊的带状疱疹发生在2例参与者中(带状疱疹活疫苗组1例;安慰剂组1例),均与疫苗株无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Herpes zoster (HZ) risk is increased in human immunodeficiency virus (HIV)-infected persons. Live attenuated zoster vaccine (ZV) reduces HZ incidence and severity in adults; safety and immunogenicity data in HIV-infected adults are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled trial in HIV-infected adults virally suppressed on antiretroviral therapy (ART). Participants, stratified by CD4+ count (200-349 or ≥350 cells/µL), were randomized 3:1 to receive ZV or placebo on day 0 and week 6. The primary endpoint was serious adverse event or grade 3/4 signs/symptoms within 6 weeks after each dose. Immunogenicity (varicella zoster virus [VZV]-specific glycoprotein enzyme-linked immunosorbent assay and interferon-γ enzyme-linked immunospot assay responses) was assessed at 6 and 12 weeks postvaccination. RESULTS: Of 395 participants (296 ZV vs 99 placebo), 84% were male, 47% white, 29% black, and 22% Hispanic; median age was 49 years. Safety endpoints occurred in 15 ZV and 2 placebo recipients (5.1% [95% confidence interval {CI}, 2.9%-8.2%] vs 2.1% [95% CI, .3%-7.3%]; P = .26). Injection site reactions occurred in 42% of ZV (95% CI, 36.3%-47.9%) vs 12.4% of placebo recipients (95% CI, 6.6%-20.6%) (P < .001). Week 12 median natural log VZV antibody titer was higher for ZV (6.30 [Q1, Q3, 5.64, 6.96]) vs placebo (5.48 [Q1, Q3, 4.63, 6.44]; P < .001) overall and in the high CD4+ stratum (P = .003). VZV antibody titers were similar after 1 or 2 ZV doses. Polymerase chain reaction-confirmed HZ occurred in 2 participants (1 ZV; 1 placebo); none was vaccine strain related. CONCLUSIONS: Two doses of ZV in HIV-infected adults suppressed on ART with CD4+ counts ≥200 cells/µL were safe and immunogenic. CLINICAL TRIALS REGISTRATION: NCT00851786.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Benson CA, Andersen JW, Macatangay BJC, et al. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clin Infect Dis. 2018. PMID: 29590326. doi:10.1093/cid/ciy242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。